摘要
目的观察地西他滨联合CAG方案应用于骨髓增生异常综合征治疗的临床效果。方法选取2007年2月至2012年1月诊治的骨髓增生异常综合征患者共73例,分为治疗组(37例)和对照组(36例),对照组实施CAG方案治疗,治疗组患者实施CAG方案与地西他滨联合治疗。比较两组患者治疗前后血管内皮生长因子变化,治疗有效率,生存时间及不良反应。结果治疗后1、3、7、14d,两组患者的血管内皮生长因子水平均明显低于治疗前(P<0.05),且治疗组较对照组降低更明显,差异均有统计学意义(P<0.05);治疗组和对照组的治疗总有效率分别为75.6%和61.1%,治疗组高于对照组,差异有统计学意义(P<0.05);两组总体生存时间和无病生存时间对比,治疗组均明显优于对照组,差异有统计学意义(P<0.05);治疗组的不良反应发生率(67.2%)明显优于对照组(77.8%),差异有统计学意义(P<0.05)。结论地西他滨与CAG方案联合治疗骨髓增生异常综合征,患者生存时间长,效果明显,值得应用。
Objective To observe the clinical effect of decitabine combined with CAG scheme in the treatment of myelodysplastic syndrome.Methods 73 cases of myelodysplastic syndrome in our hospital from February 2007 to January 2012 were chosen and randomly divided into the control group（36cases）and the treatment group（37cases）.The control group was treated with the CAG regimen,while the treatment group was given the CAG scheme combined with decitabine treatment.The changes of vascular endothelial growth factor（VEGF）before treatment and after treatment,total effective rate,survival time and adverse reactions were compared between the two groups.ResultsThe VEGF levels on 1,3,7,14 dafter treatment in the two group were all significantly lower than those before therapy（P〈0.05）,moreover the decrease in the treatment group was more significant than the control group,the difference was statistically significant（P〈0.05）;the total effective rates of the treatment group and the control group were75.6% and 61.1% respectively,the treatment group was higher than the control group with statistical difference（P〈0.05）;the overall survival time and disease-free survival time in the treatment group were significantly better than those in the control group,the differences were statistically significant（P〈0.05）;the incidence rate of adverse reactions in the treatment group was 67.2%,which was significantly lower than 77.8%in the control group,the differences were statistically significant（P〈0.05）.Conclusion Decitabine combined with CAG scheme in treating myelodysplastic syndrome has long survival time,obvious effect and is worthy of promotion.
出处
《检验医学与临床》
CAS
2015年第22期3339-3341,共3页
Laboratory Medicine and Clinic
